HomeFranceEckuity Capital Closes $150M Fund; Appoints Dr Victoria Manax Rutson as Partner

Eckuity Capital Closes $150M Fund; Appoints Dr Victoria Manax Rutson as Partner

Eckuity Capital

Eckuity Capital, a New York-, London, UK- and Paris, France-based growth and venture capital investor, recently closed Eckuity Capital Fund I, LP, at $155m.

The fund will invest selectively in a portfolio of venture and growth companies in three healthcare sectors of focus: Therapeutics, MedTech and Digital health.

Led by managing partners Vishal Jain and Youssef Sebban, Eckuity Capital is a global growth and venture capital investor which invests in life science, healthcare and tech companies that can deliver a positive impact on healthcare outcomes, wellness, and enhancement of the human condition. The firm brings together a team of global investment professionals with strong scientific, medical and business expertise to back companies advancing artificial intelligence (AI), robotics, the Internet of Things (IoT), 3D printing, genetic engineering, genomics, biology, quantum computing, and other technologies.

The firm, which currently manages nine portfolio companies across its three healthcare sectors, also appointed Dr Victoria Manax Rutson as a new partner. Dr Manax is a medical oncologist with over two decades of expertise in the pharmaceutical/biotech industry, focusing on global drug/device development, nanomedicines, and product launch /commercialization. She has made contributions to the field, particularly in shaping clinical trial landscapes with adaptive platform designs and biomarker integration.

She played a pivotal role in the development, approval, and launch of billion-dollar products, including the standard of care for pancreatic cancer. Holding multiple leadership/executive positions in companies such as Abraxis Bioscience, Celgene (BMS), MedSurge PI, and Duo Oncology, Dr Manax has also served as the inaugural Chief Medical Officer for the Pancreatic Cancer Action Network, earning recognition as a respected panelist among FDA and regulatory agencies worldwide.

VCWire

13/03/2024